The biopharma industry faced mounting headwinds in 2023, with several major players announcing significant restructuring efforts. Faced with expiring patents, inflation and rising interest rates, and heightened FTC scrutiny, companies looked to trim expenses and refocus their businesses. The ebbing tied of the pandemic posed a challenge for a number of drug developers as well.…